Kestra Medical Technologies (NASDAQ:KMTS) Stock Rating Upgraded by Wall Street Zen

Kestra Medical Technologies (NASDAQ:KMTS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Royal Bank Of Canada set a $30.00 price objective on Kestra Medical Technologies in a research note on Tuesday, September 15th. Evercore assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.00.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $29.69 on Friday. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The business has a 50-day simple moving average of $26.69 and a 200-day simple moving average of $23.82. The stock has a market cap of $1.77 billion, a PE ratio of -11.12 and a beta of 0.45. Kestra Medical Technologies has a 52-week low of $17.34 and a 52-week high of $31.06.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The firm had revenue of $30.97 million during the quarter. On average, equities analysts expect that Kestra Medical Technologies will post -2.45 EPS for the current year.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, Director Raymond W. Cohen sold 3,330 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total transaction of $97,502.40. Following the transaction, the director owned 54,790 shares of the company’s stock, valued at $1,604,251.20. This trade represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $29.56, for a total value of $443,400.00. Following the completion of the transaction, the insider owned 445,215 shares of the company’s stock, valued at approximately $13,160,555.40. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 358,301 shares of company stock valued at $9,854,350 over the last 90 days. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in KMTS. Sei Investments Co. boosted its holdings in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after purchasing an additional 5,731 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after purchasing an additional 22,471 shares in the last quarter. Corient Private Wealth LP increased its position in shares of Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after purchasing an additional 44,839 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at about $603,000.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.